Tango Therapeutics, Inc. Letters of Credit Outstanding, Amount
Tango Therapeutics, Inc. (TNGX) had Letters of Credit Outstanding, Amount of $2.60 million as of 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes
us-gaap:LettersOfCreditOutstandingAmount · last filed 2026-03-05
- 2024-12-31: Letters of Credit Outstanding, Amount $2.60M.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2024-12-31 | $2.60M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |